Current Document Type: HighlightsVideoPage Tiffany Richards, PhD, ANP-BC, AOCNP, on t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: New Findings on Venetoclax Combination - JADPRO

Watch More Highlights

Tiffany Richards, PhD, ANP-BC, AOCNP®, of The University of Texas MD Anderson Cancer Center, dives into an analysis of minimal residual disease (MRD) negativity from a phase 1/2 trial in t(11;14)-positive relapsed/refractory multiple myeloma. The combination of venetoclax, daratumumab, and dexamethasone showed higher rates of MRD negativity compared with the combination of bortezomib, daratumumab, and dexamethasone (38% vs. 8%; Abstract 338).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.